Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "PPL"

2432 News Found

USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab
Drug Approval | May 08, 2024

USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab

Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor


Aptar Closures introduces new e-Commerce disc top closure for beauty, personal and home care applications
News | May 08, 2024

Aptar Closures introduces new e-Commerce disc top closure for beauty, personal and home care applications

Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees


Zydus’ new drug application of Desidustat tablets accepted by China Medical System Holdings
Drug Approval | April 23, 2024

Zydus’ new drug application of Desidustat tablets accepted by China Medical System Holdings

Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients


Cupid to supply Rs. 23.07 crore female condoms in Brazil
News | April 12, 2024

Cupid to supply Rs. 23.07 crore female condoms in Brazil

Total value of the supplies of FC will be US$ 2.773 million


NMPA accepts supplemental Biologics License Application for enfortumab vedotin with Keytruda for treatment of bladder cancer
Drug Approval | March 30, 2024

NMPA accepts supplemental Biologics License Application for enfortumab vedotin with Keytruda for treatment of bladder cancer

If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy


Cipla appoints Venkata Sai Mungara as Global Head – Supply Chain
People | March 17, 2024

Cipla appoints Venkata Sai Mungara as Global Head – Supply Chain

Mungara has over 25+ years of experience in the supply chain domain


EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer
Drug Approval | January 29, 2024

EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer

Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival


Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator
News | January 19, 2024

Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator

Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator


Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market
Drug Approval | January 19, 2024

Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market

Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets